TW201028406A - 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use - Google Patents

5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use Download PDF

Info

Publication number: TW201028406A
Authority: TW; Taiwan
Prior art keywords: group; alkyl; aryl; crc6; substituted
Prior art date: 2008-12-23

Application number

TW098144465A

Other languages

English (en)

Chinese (zh)

Inventor

David Alexander Learmonth

Da Silva Patricio Manuel Vieira Araujo Soares

Original Assignee

Bial Portela & Ca Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-23

Filing date

2009-12-23

Publication date

2010-08-01

2009-12-23 Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa

2010-08-01 Publication of TW201028406A publication Critical patent/TW201028406A/zh

Links

125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 69
150000001875 compounds Chemical class 0.000 claims abstract description 68
229910052760 oxygen Inorganic materials 0.000 claims abstract description 42
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 40
239000001257 hydrogen Substances 0.000 claims abstract description 40
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 28
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 19
229910052757 nitrogen Inorganic materials 0.000 claims abstract description 17
229910052717 sulfur Inorganic materials 0.000 claims abstract description 16
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 12
125000005842 heteroatom Chemical group 0.000 claims abstract description 9
150000002148 esters Chemical class 0.000 claims abstract description 4
125000000217 alkyl group Chemical group 0.000 claims description 153
-1 sulfonyloxy group Chemical group 0.000 claims description 128
125000003277 amino group Chemical group 0.000 claims description 126
125000001153 fluoro group Chemical group F* 0.000 claims description 88
239000007789 gas Substances 0.000 claims description 56
125000001246 bromo group Chemical group Br* 0.000 claims description 52
125000003118 aryl group Chemical group 0.000 claims description 51
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 48
125000004093 cyano group Chemical group *C#N 0.000 claims description 46
125000003545 alkoxy group Chemical group 0.000 claims description 44
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 42
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 40
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 40
239000001301 oxygen Substances 0.000 claims description 39
125000003396 thiol group Chemical group [H]S* 0.000 claims description 39
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 38
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine group Chemical group NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 38
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 37
150000001412 amines Chemical class 0.000 claims description 32
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 32
229920006395 saturated elastomer Polymers 0.000 claims description 32
229910006074 SO2NH2 Inorganic materials 0.000 claims description 31
125000002346 iodo group Chemical group I* 0.000 claims description 31
150000003573 thiols Chemical group 0.000 claims description 27
125000004429 atom Chemical group 0.000 claims description 24
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 24
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 23
125000001309 chloro group Chemical group Cl* 0.000 claims description 23
125000000565 sulfonamide group Chemical group 0.000 claims description 23
125000001424 substituent group Chemical group 0.000 claims description 21
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 20
239000000126 substance Substances 0.000 claims description 19
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 18
125000004104 aryloxy group Chemical group 0.000 claims description 18
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical group [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims description 17
206010028980 Neoplasm Diseases 0.000 claims description 16
125000000041 C6-C10 aryl group Chemical group 0.000 claims description 15
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 13
125000003282 alkyl amino group Chemical group 0.000 claims description 13
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 13
239000011593 sulfur Chemical group 0.000 claims description 13
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
208000002193 Pain Diseases 0.000 claims description 9
150000002431 hydrogen Chemical class 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
150000003973 alkyl amines Chemical class 0.000 claims description 8
230000001684 chronic effect Effects 0.000 claims description 8
125000000623 heterocyclic group Chemical group 0.000 claims description 8
125000005647 linker group Chemical group 0.000 claims description 8
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 8
230000001154 acute effect Effects 0.000 claims description 7
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
239000011737 fluorine Substances 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical class 0.000 claims description 7
ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical group O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims description 7
125000005129 aryl carbonyl group Chemical group 0.000 claims description 6
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 6
125000003386 piperidinyl group Chemical group 0.000 claims description 6
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 6
206010011224 Cough Diseases 0.000 claims description 5
125000005157 alkyl carboxy group Chemical group 0.000 claims description 5
125000004956 cyclohexylene group Chemical group 0.000 claims description 5
125000004979 cyclopentylene group Chemical group 0.000 claims description 5
208000011580 syndromic disease Diseases 0.000 claims description 5
239000000052 vinegar Substances 0.000 claims description 5
235000021419 vinegar Nutrition 0.000 claims description 5
MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 claims description 4
208000000884 Airway Obstruction Diseases 0.000 claims description 4
208000024827 Alzheimer disease Diseases 0.000 claims description 4
208000009079 Bronchial Spasm Diseases 0.000 claims description 4
208000014181 Bronchial disease Diseases 0.000 claims description 4
206010006458 Bronchitis chronic Diseases 0.000 claims description 4
206010006482 Bronchospasm Diseases 0.000 claims description 4
206010014561 Emphysema Diseases 0.000 claims description 4
208000010412 Glaucoma Diseases 0.000 claims description 4
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 4
201000002661 Spondylitis Diseases 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 4
206010006451 bronchitis Diseases 0.000 claims description 4
208000007451 chronic bronchitis Diseases 0.000 claims description 4
230000003111 delayed effect Effects 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
230000005764 inhibitory process Effects 0.000 claims description 4
208000023504 respiratory system disease Diseases 0.000 claims description 4
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 4
208000000094 Chronic Pain Diseases 0.000 claims description 3
206010012442 Dermatitis contact Diseases 0.000 claims description 3
206010014967 Ependymoma Diseases 0.000 claims description 3
201000005569 Gout Diseases 0.000 claims description 3
206010020751 Hypersensitivity Diseases 0.000 claims description 3
208000005298 acute pain Diseases 0.000 claims description 3
208000006673 asthma Diseases 0.000 claims description 3
210000004027 cell Anatomy 0.000 claims description 3
208000010247 contact dermatitis Diseases 0.000 claims description 3
125000004122 cyclic group Chemical group 0.000 claims description 3
235000014113 dietary fatty acids Nutrition 0.000 claims description 3
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
239000000194 fatty acid Substances 0.000 claims description 3
229930195729 fatty acid Natural products 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
230000004410 intraocular pressure Effects 0.000 claims description 3
150000002576 ketones Chemical group 0.000 claims description 3
239000000463 material Substances 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
239000002243 precursor Substances 0.000 claims description 3
206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
238000007363 ring formation reaction Methods 0.000 claims description 3
125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 2
208000019901 Anxiety disease Diseases 0.000 claims description 2
208000023275 Autoimmune disease Diseases 0.000 claims description 2
201000006474 Brain Ischemia Diseases 0.000 claims description 2
206010006895 Cachexia Diseases 0.000 claims description 2
208000024172 Cardiovascular disease Diseases 0.000 claims description 2
206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
208000027932 Collagen disease Diseases 0.000 claims description 2
206010010741 Conjunctivitis Diseases 0.000 claims description 2
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
208000012661 Dyskinesia Diseases 0.000 claims description 2
208000014094 Dystonic disease Diseases 0.000 claims description 2
208000030814 Eating disease Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
206010020772 Hypertension Diseases 0.000 claims description 2
208000012659 Joint disease Diseases 0.000 claims description 2
201000009906 Meningitis Diseases 0.000 claims description 2
208000019695 Migraine disease Diseases 0.000 claims description 2
ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical group [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 2
206010028813 Nausea Diseases 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims description 2
208000025966 Neurological disease Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
206010033799 Paralysis Diseases 0.000 claims description 2
206010033864 Paranoia Diseases 0.000 claims description 2
208000027099 Paranoid disease Diseases 0.000 claims description 2
206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
201000004681 Psoriasis Diseases 0.000 claims description 2
208000028017 Psychotic disease Diseases 0.000 claims description 2
206010039085 Rhinitis allergic Diseases 0.000 claims description 2
206010039491 Sarcoma Diseases 0.000 claims description 2
208000000323 Tourette Syndrome Diseases 0.000 claims description 2
208000016620 Tourette disease Diseases 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
206010044565 Tremor Diseases 0.000 claims description 2
206010047115 Vasculitis Diseases 0.000 claims description 2
241000700605 Viruses Species 0.000 claims description 2
206010047700 Vomiting Diseases 0.000 claims description 2
208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
201000010105 allergic rhinitis Diseases 0.000 claims description 2
208000022531 anorexia Diseases 0.000 claims description 2
230000036506 anxiety Effects 0.000 claims description 2
125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
208000022362 bacterial infectious disease Diseases 0.000 claims description 2
208000013355 benign neoplasm of brain Diseases 0.000 claims description 2
206010004398 benign neoplasm of skin Diseases 0.000 claims description 2
210000001185 bone marrow Anatomy 0.000 claims description 2
201000011510 cancer Diseases 0.000 claims description 2
206010008118 cerebral infarction Diseases 0.000 claims description 2
238000002512 chemotherapy Methods 0.000 claims description 2
208000018631 connective tissue disease Diseases 0.000 claims description 2
208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
206010061428 decreased appetite Diseases 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
208000010643 digestive system disease Diseases 0.000 claims description 2
235000014632 disordered eating Nutrition 0.000 claims description 2
208000002173 dizziness Diseases 0.000 claims description 2
208000010118 dystonia Diseases 0.000 claims description 2
230000000408 embryogenic effect Effects 0.000 claims description 2
206010015037 epilepsy Diseases 0.000 claims description 2
208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
208000014674 injury Diseases 0.000 claims description 2
230000003902 lesion Effects 0.000 claims description 2
206010025135 lupus erythematosus Diseases 0.000 claims description 2
210000001595 mastoid Anatomy 0.000 claims description 2
201000001441 melanoma Diseases 0.000 claims description 2
206010027599 migraine Diseases 0.000 claims description 2
235000013336 milk Nutrition 0.000 claims description 2
239000008267 milk Substances 0.000 claims description 2
210000004080 milk Anatomy 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
201000000050 myeloid neoplasm Diseases 0.000 claims description 2
208000031225 myocardial ischemia Diseases 0.000 claims description 2
230000008693 nausea Effects 0.000 claims description 2
230000009826 neoplastic cell growth Effects 0.000 claims description 2
208000004296 neuralgia Diseases 0.000 claims description 2
230000004770 neurodegeneration Effects 0.000 claims description 2
208000015122 neurodegenerative disease Diseases 0.000 claims description 2
230000000926 neurological effect Effects 0.000 claims description 2
208000021722 neuropathic pain Diseases 0.000 claims description 2
230000002093 peripheral effect Effects 0.000 claims description 2
208000024724 pineal body neoplasm Diseases 0.000 claims description 2
238000002360 preparation method Methods 0.000 claims description 2
208000020016 psychiatric disease Diseases 0.000 claims description 2
230000002685 pulmonary effect Effects 0.000 claims description 2
206010039083 rhinitis Diseases 0.000 claims description 2
201000002859 sleep apnea Diseases 0.000 claims description 2
208000019116 sleep disease Diseases 0.000 claims description 2
210000004500 stellate cell Anatomy 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
230000008733 trauma Effects 0.000 claims description 2
230000008673 vomiting Effects 0.000 claims description 2
125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 4
206010061218 Inflammation Diseases 0.000 claims 3
230000004054 inflammatory process Effects 0.000 claims 3
125000004149 thio group Chemical group *S* 0.000 claims 3
210000003462 vein Anatomy 0.000 claims 3
150000001335 aliphatic alkanes Chemical class 0.000 claims 2
201000000053 blastoma Diseases 0.000 claims 2
201000008184 embryoma Diseases 0.000 claims 2
150000004665 fatty acids Chemical class 0.000 claims 2
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 1
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims 1
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
206010008748 Chorea Diseases 0.000 claims 1
201000004624 Dermatitis Diseases 0.000 claims 1
206010058314 Dysplasia Diseases 0.000 claims 1
241000238631 Hexapoda Species 0.000 claims 1
208000019693 Lung disease Diseases 0.000 claims 1
206010029260 Neuroblastoma Diseases 0.000 claims 1
208000005890 Neuroma Diseases 0.000 claims 1
201000010133 Oligodendroglioma Diseases 0.000 claims 1
208000007641 Pinealoma Diseases 0.000 claims 1
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
208000034189 Sclerosis Diseases 0.000 claims 1
125000003158 alcohol group Chemical group 0.000 claims 1
125000004414 alkyl thio group Chemical group 0.000 claims 1
208000030961 allergic reaction Diseases 0.000 claims 1
MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims 1
125000005577 anthracene group Chemical group 0.000 claims 1
125000005110 aryl thio group Chemical group 0.000 claims 1
208000012601 choreatic disease Diseases 0.000 claims 1
125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
230000007812 deficiency Effects 0.000 claims 1
208000001848 dysentery Diseases 0.000 claims 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical group O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims 1
125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
239000008187 granular material Substances 0.000 claims 1
208000026278 immune system disease Diseases 0.000 claims 1
125000002512 iodyl group Chemical group O=I(=O)[*] 0.000 claims 1
GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical group C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 claims 1
230000036651 mood Effects 0.000 claims 1
230000002981 neuropathic effect Effects 0.000 claims 1
125000004076 pyridyl group Chemical group 0.000 claims 1
230000001568 sexual effect Effects 0.000 claims 1
125000004646 sulfenyl group Chemical group S(*)* 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 6
239000003940 fatty acid amidase inhibitor Substances 0.000 abstract description 2
229940002612 prodrug Drugs 0.000 abstract description 2
239000000651 prodrug Substances 0.000 abstract description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
229910052796 boron Inorganic materials 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 85
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 64
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 20
239000000243 solution Substances 0.000 description 18
239000000203 mixture Substances 0.000 description 13
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
102100027297 Fatty acid 2-hydroxylase Human genes 0.000 description 9
101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 description 9
101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 8
239000007787 solid Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 7
239000005457 ice water Substances 0.000 description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
239000002904 solvent Substances 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
239000002253 acid Substances 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
125000000753 cycloalkyl group Chemical group 0.000 description 5
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
125000001624 naphthyl group Chemical group 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 3
125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 3
150000001356 alkyl thiols Chemical class 0.000 description 3
LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 3
239000012267 brine Substances 0.000 description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000000354 decomposition reaction Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
SEPPVOUBHWNCAW-FNORWQNLSA-N (E)-4-oxonon-2-enal Chemical compound CCCCCC(=O)\C=C\C=O SEPPVOUBHWNCAW-FNORWQNLSA-N 0.000 description 2
YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
UBUDBCZCLQPTIE-UHFFFAOYSA-N 3-(4-amino-3-methoxyphenyl)-5-(2,4-difluorophenoxy)-1,3,4-oxadiazol-2-one Chemical compound C1=C(N)C(OC)=CC(N2C(OC(OC=3C(=CC(F)=CC=3)F)=N2)=O)=C1 UBUDBCZCLQPTIE-UHFFFAOYSA-N 0.000 description 2
NZVKTUYSHCWKCL-UHFFFAOYSA-N 3h-1,3-oxazol-2-one;2,2,2-trifluoroacetic acid Chemical compound O=C1NC=CO1.OC(=O)C(F)(F)F NZVKTUYSHCWKCL-UHFFFAOYSA-N 0.000 description 2
ZVDRVTUQPJZIIY-UHFFFAOYSA-N 3h-1,3-oxazol-2-one;hydrochloride Chemical compound Cl.O=C1NC=CO1 ZVDRVTUQPJZIIY-UHFFFAOYSA-N 0.000 description 2
LLBZPESJRQGYMB-UHFFFAOYSA-N 4-one Natural products O1C(C(=O)CC)CC(C)C11C2(C)CCC(C3(C)C(C(C)(CO)C(OC4C(C(O)C(O)C(COC5C(C(O)C(O)CO5)OC5C(C(OC6C(C(O)C(O)C(CO)O6)O)C(O)C(CO)O5)OC5C(C(O)C(O)C(C)O5)O)O4)O)CC3)CC3)=C3C2(C)CC1 LLBZPESJRQGYMB-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
239000005909 Kieselgur Substances 0.000 description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229910000831 Steel Inorganic materials 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
ROFVXGGUISEHAM-UHFFFAOYSA-N URB597 Chemical compound NC(=O)C1=CC=CC(C=2C=C(OC(=O)NC3CCCCC3)C=CC=2)=C1 ROFVXGGUISEHAM-UHFFFAOYSA-N 0.000 description 2
MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
125000003710 aryl alkyl group Chemical group 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
RCJVRSBWZCNNQT-UHFFFAOYSA-N dichloridooxygen Chemical compound ClOCl RCJVRSBWZCNNQT-UHFFFAOYSA-N 0.000 description 2
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Natural products C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000002621 endocannabinoid Substances 0.000 description 2
125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
QEWYKACRFQMRMB-UHFFFAOYSA-M fluoroacetate Chemical compound [O-]C(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-M 0.000 description 2
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
239000012528 membrane Substances 0.000 description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
210000000578 peripheral nerve Anatomy 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
150000004032 porphyrins Chemical class 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
125000000719 pyrrolidinyl group Chemical group 0.000 description 2
229910052707 ruthenium Inorganic materials 0.000 description 2
239000002689 soil Substances 0.000 description 2
239000010959 steel Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
PMJHHCWVYXUKFD-SNAWJCMRSA-N (E)-1,3-pentadiene Chemical group C\C=C\C=C PMJHHCWVYXUKFD-SNAWJCMRSA-N 0.000 description 1
VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
238000005160 1H NMR spectroscopy Methods 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
UHGSXJOONHIRAJ-UHFFFAOYSA-N 3-phenyl-1,3,4-oxadiazol-2-one Chemical class O=C1OC=NN1C1=CC=CC=C1 UHGSXJOONHIRAJ-UHFFFAOYSA-N 0.000 description 1
JUGXELOOHRVUJT-UHFFFAOYSA-N 3H-1,3,4-oxadiazol-2-one dihydrochloride Chemical compound C1=NNC(=O)O1.Cl.Cl JUGXELOOHRVUJT-UHFFFAOYSA-N 0.000 description 1
QKYCBLWVBWAYDT-UHFFFAOYSA-N 3H-1,3,4-oxadiazol-2-one hydrochloride Chemical compound Cl.O=c1[nH]nco1 QKYCBLWVBWAYDT-UHFFFAOYSA-N 0.000 description 1
WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical compound O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
OQLZINXFSUDMHM-UHFFFAOYSA-N Acetamidine Chemical compound CC(N)=N OQLZINXFSUDMHM-UHFFFAOYSA-N 0.000 description 1
JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
SSUFDOMYCBCHML-UHFFFAOYSA-N CCCCC[S](=O)=O Chemical group CCCCC[S](=O)=O SSUFDOMYCBCHML-UHFFFAOYSA-N 0.000 description 1
JNSAWGNVZMPYJI-UHFFFAOYSA-N CCNS(=O)=O Chemical compound CCNS(=O)=O JNSAWGNVZMPYJI-UHFFFAOYSA-N 0.000 description 1
101150072608 CVC1 gene Proteins 0.000 description 1
101150010802 CVC2 gene Proteins 0.000 description 1
102000018208 Cannabinoid Receptor Human genes 0.000 description 1
108050007331 Cannabinoid receptor Proteins 0.000 description 1
241000252505 Characidae Species 0.000 description 1
NQMLURFNGGXIND-UHFFFAOYSA-N Cl.O=C1CC=CN1 Chemical compound Cl.O=C1CC=CN1 NQMLURFNGGXIND-UHFFFAOYSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
101150042613 FA2H gene Proteins 0.000 description 1
101150008770 FAAH gene Proteins 0.000 description 1
XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical group FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
102000004157 Hydrolases Human genes 0.000 description 1
108090000604 Hydrolases Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
208000000172 Medulloblastoma Diseases 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 1
KWKZCGMJGHHOKJ-ZKWNWVNESA-N Methyl Arachidonyl Fluorophosphonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCCP(F)(=O)OC KWKZCGMJGHHOKJ-ZKWNWVNESA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
238000011785 NMRI mouse Methods 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
YNKFSFDIDFUEQP-UHFFFAOYSA-N O1C(NC=C1)=O.[Bi] Chemical group O1C(NC=C1)=O.[Bi] YNKFSFDIDFUEQP-UHFFFAOYSA-N 0.000 description 1
JVRHADZWRWBICE-UHFFFAOYSA-N O=S(=O)NC1=CC=CC=C1 Chemical compound O=S(=O)NC1=CC=CC=C1 JVRHADZWRWBICE-UHFFFAOYSA-N 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
206010063897 Renal ischaemia Diseases 0.000 description 1
101100137598 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRM6 gene Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
240000008866 Ziziphus nummularia Species 0.000 description 1
FUFVKLQESJNNAN-ZZJGABIISA-M [(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-hydroxy-2-phenylacetate;bromide Chemical compound [Br-].C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2OC(=O)C(O)C1=CC=CC=C1 FUFVKLQESJNNAN-ZZJGABIISA-M 0.000 description 1
UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
206010002022 amyloidosis Diseases 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
125000005418 aryl aryl group Chemical group 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
CMANTJGPMZJEQC-UHFFFAOYSA-N benzylsulfanium;fluoride Chemical compound [F-].[SH2+]CC1=CC=CC=C1 CMANTJGPMZJEQC-UHFFFAOYSA-N 0.000 description 1
230000002902 bimodal effect Effects 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
230000037396 body weight Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000006251 butylcarbonyl group Chemical group 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
208000035269 cancer or benign tumor Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229950005499 carbon tetrachloride Drugs 0.000 description 1
150000004649 carbonic acid derivatives Chemical class 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003245 coal Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
125000006612 decyloxy group Chemical group 0.000 description 1
230000002950 deficient Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
125000005066 dodecenyl group Chemical group C(=CCCCCCCCCCC)* 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethanethiol Chemical compound CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
125000004494 ethyl ester group Chemical group 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
UQSQSQZYBQSBJZ-UHFFFAOYSA-M fluorosulfonate Chemical compound [O-]S(F)(=O)=O UQSQSQZYBQSBJZ-UHFFFAOYSA-M 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000005017 glioblastoma Diseases 0.000 description 1
125000001072 heteroaryl group Chemical group 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
125000005597 hydrazone group Chemical group 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
229950003188 isovaleryl diethylamide Drugs 0.000 description 1
238000009533 lab test Methods 0.000 description 1
QENHCSSJTJWZAL-UHFFFAOYSA-N magnesium sulfide Chemical compound [Mg+2].[S-2] QENHCSSJTJWZAL-UHFFFAOYSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229910052750 molybdenum Inorganic materials 0.000 description 1
239000011733 molybdenum Substances 0.000 description 1
YWWNNLPSZSEZNZ-UHFFFAOYSA-N n,n-dimethyldecan-1-amine Chemical compound CCCCCCCCCCN(C)C YWWNNLPSZSEZNZ-UHFFFAOYSA-N 0.000 description 1
125000006126 n-butyl sulfonyl group Chemical group 0.000 description 1
VTHOTOFWYDBNID-UHFFFAOYSA-N n-decylaniline Chemical compound CCCCCCCCCCNC1=CC=CC=C1 VTHOTOFWYDBNID-UHFFFAOYSA-N 0.000 description 1
RDXBZXWKSIEKKS-UHFFFAOYSA-N n-ethyldecan-1-amine Chemical compound CCCCCCCCCCNCC RDXBZXWKSIEKKS-UHFFFAOYSA-N 0.000 description 1
IKVDMBQGHZVMRN-UHFFFAOYSA-N n-methyldecan-1-amine Chemical compound CCCCCCCCCCNC IKVDMBQGHZVMRN-UHFFFAOYSA-N 0.000 description 1
125000006124 n-propyl sulfonyl group Chemical group 0.000 description 1
125000006252 n-propylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
125000005185 naphthylcarbonyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
208000007538 neurilemmoma Diseases 0.000 description 1
230000002232 neuromuscular Effects 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000012740 non-selective inhibitor Substances 0.000 description 1
125000005187 nonenyl group Chemical group C(=CCCCCCCC)* 0.000 description 1
125000004365 octenyl group Chemical group C(=CCCCCCC)* 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical group [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
125000003544 oxime group Chemical group 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
244000045947 parasite Species 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000005561 phenanthryl group Chemical group 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
125000001129 phenylbutoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
229940067157 phenylhydrazine Drugs 0.000 description 1
125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
239000011435 rock Substances 0.000 description 1
YBCAZPLXEGKKFM-UHFFFAOYSA-K ruthenium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Ru+3] YBCAZPLXEGKKFM-UHFFFAOYSA-K 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000758 substrate Substances 0.000 description 1
125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
238000005486 sulfidation Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 1
125000005063 tetradecenyl group Chemical group C(=CCCCCCCCCCCCC)* 0.000 description 1
150000003536 tetrazoles Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
YGNGABUJMXJPIJ-UHFFFAOYSA-N thiatriazole Chemical compound C1=NN=NS1 YGNGABUJMXJPIJ-UHFFFAOYSA-N 0.000 description 1
239000003451 thiazide diuretic agent Substances 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
229910052721 tungsten Inorganic materials 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
125000002114 valyl group Chemical group 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/13—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

TW098144465A 2008-12-23 2009-12-23 5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use TW201028406A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US20354908P	2008-12-23	2008-12-23

Publications (1)

Publication Number	Publication Date
TW201028406A true TW201028406A (en)	2010-08-01

Family

ID=41722972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW098144465A TW201028406A (en)	2008-12-23	2009-12-23	5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use

Country Status (3)

Country	Link
AR (1)	AR074978A1 (fr)
TW (1)	TW201028406A (fr)
WO (1)	WO2010074587A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011085216A2 (fr)	2010-01-08	2011-07-14	Ironwood Pharmaceuticals, Inc.	Utilisation d'inhibiteurs de faah pour traiter la maladie de parkinson et le syndrome des jambes sans repos
US20130224151A1 (en)	2010-03-31	2013-08-29	United States Of America	Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS531335B2 (fr)	1971-11-29	1978-01-18
US4076824A (en)	1975-02-03	1978-02-28	Rhone-Poulenc Industries	Anthelmintic oxadiazolinone derivatives
FR2605007A2 (fr) *	1986-05-07	1988-04-15	Rhone Poulenc Agrochimie	Herbicides de type sulfonyluree, leur preparation, les compositions les contenant et leur utilisation
US5236939A (en)	1989-09-23	1993-08-17	Bayer Aktiengesellschaft	Substituted 1,3,4-oxa(thia)diazolinones process for their preparation and their use of combating endoparasites
DE3931843A1 (de)	1989-09-23	1991-04-04	Bayer Ag	Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
DE19942354A1 (de)	1999-09-04	2001-03-08	Aventis Pharma Gmbh	Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
TR200401217T4 (tr)	2000-03-07	2004-06-21	Aventis Pharma Deutschland Gmbh	İkameli 3-Fenil-5-Alkoksi-1,3,4-Oksdiazol-2-one (ve) hormona duyarlı lipazın önlenmesinde kullanılması
US7205321B2 (en)	2001-11-15	2007-04-17	Eli Lilly And Company	Peroxisome proliferator activated receptor alpha agonists
DE10208987A1 (de)	2002-02-28	2003-09-11	Aventis Pharma Gmbh	Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
DE10208986A1 (de)	2002-02-28	2003-09-11	Aventis Pharma Gmbh	Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
MXPA05000053A (es) *	2002-07-12	2005-04-08	Aventis Pharma Gmbh	Benzoilureas heterociclicamente sustituidas, metodo para su produccion y su uso como medicamentos.
JP2011507952A (ja) *	2007-12-27	2011-03-10	バイアル−ポルテラアンドシーエー，エス．エー．	医療用途用５−ｏ−置換３−ｎ−フェニル−１、３、４−オキサジアゾロン類

2009
- 2009-12-23 TW TW098144465A patent/TW201028406A/zh unknown
- 2009-12-23 AR ARP090105095A patent/AR074978A1/es unknown
- 2009-12-23 WO PCT/PT2009/000079 patent/WO2010074587A2/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2010074587A2 (fr)	2010-07-01
WO2010074587A3 (fr)	2010-11-11
AR074978A1 (es)	2011-03-02

Publication	Publication Date	Title
KR101099849B1 (ko)	2011-12-28	Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
CN101501028B (zh)	2013-09-11	2-(杂环基苄基)哒嗪酮衍生物
CA2649924C (fr)	2014-08-19	Inhibiteurs de la c-fms kinase
US8211920B2 (en)	2012-07-03	6-oxo-1,6-dihydropyridine derivatives as inhibitors of MEK and methods of use thereof
WO2007070892A2 (fr)	2007-06-21	Composes indole utiles
US20110183981A1 (en)	2011-07-28	Heterocyclic inhibitors of mek and methods of use thereof
TW200908984A (en)	2009-03-01	Pyridyl derivatives, their preparation and use
TW201030009A (en)	2010-08-16	Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
US20090075985A1 (en)	2009-03-19	Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease
JP2010536719A (ja)	2010-12-02	６−チオキソピリダジン誘導体
CN101326167A (zh)	2008-12-17	用于治疗肿瘤的哒嗪酮衍生物
JPH04210981A (ja)	1992-08-03	アザオキシインドール誘導体
CN102272125A (zh)	2011-12-07	哒嗪酮衍生物
TW200927729A (en)	2009-07-01	4-heteroaryl-substituted phenoxyphenylacetic acid derivatives
JP2011088847A (ja)	2011-05-06	三環性化合物およびその用途
CN1291099A (zh)	2001-04-11	杂环化合物,其生产和用途
TW201028406A (en)	2010-08-01	5-O-substituted 3-N-aryl-1,3,4-oxadiazolones for medical use
TW200908967A (en)	2009-03-01	Pyrazolo-pyridinone compounds and methods of use thereof
CN1076696A (zh)	1993-09-29	药用化合物
CN102256980A (zh)	2011-11-23	3-(3-嘧啶-2-基苄基)-1，2，4-三唑并[4，3-b]嘧啶衍生物
JP2009530338A (ja)	2009-08-27	可溶性アデニル酸シクラーゼのインヒビターとしてのインドール誘導体
CN102272131A (zh)	2011-12-07	哒嗪酮衍生物
JP2009530339A (ja)	2009-08-27	可溶性アデニル酸シクラーゼインヒビター
TW201100079A (en)	2011-01-01	5-O-substituted 3-N-heteroaryl-1,3,4-oxadiazolones for medical use
US6329393B1 (en)	2001-12-11	Crystalline pharmaceutically acceptable salts of an oxazolidinone derivative